|
Simon Douglas
Simon Douglas is Chairman of Lab901. With over 20 years experience in biotech working for Amersham International, ICI and Zeneca, in a variety of commercial and technical positions, he was previously the CEO of the Life Science company Tepnel plc and Chief Executive of the VC backed start-up company DNA Research Innovations Ltd (DRI) which was acquired by Invitrogen Corporation in 2004.
Currently Simon is a non-executive director of the antibody-based therapeutics Company Fusion Antibodies, where he was previously the CEO, and also the Chief Executive of the diagnostic company Xynostics Ltd.
Any contributions will be gratefully accepted
|
The content of this website is a collection of materials gathered from a variety of sources, some of it unedited. The webmaster does not intend to claim authorship, but gives credit to the originators for their work. As work progresses, some of the content may be re-written and presented in a unique format, to which we would then be able to claim ownership. Discussion and contributions from those more knowledgeable is welcome. Last modified: Friday, 02 August 2024 |